Publications
Does delayed EBV infection contribute to rising childhood cancers?
Zhang B, Choi IK, Panaampon J, Wang Z.
Facts and hopes in the relationship of EBV with cancer immunity and immunotherapy.
Zhang B, Choi IK.
Clin Cancer Res. 2022 Oct 14;28(20):4363-4369 (Epub 2022 Jun 10). PMID: 35686929.
Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.
Choi IK, Wang Z, Ke Q, Hong M, Paul DW Jr, Fernandes SM, Hu Z, Stevens J, Guleria I, Kim HJ, Cantor H, Wucherpfennig KW, Brown JR, Ritz J, Zhang B.
Nature. 2021 Feb;590(7844):157-162 (Epub 2020 Dec 23). PMID: 33361812. Full text link.
-
Highlight by the Research Watch in CANCER DISCOVERY: Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable. 2021 Jan 15.
-
Featured in the Dana-Farber Insight: Study Suggests Novel Way of Spurring Immune Attack on B Cell Cancers. 2021 Feb 24.
BCR-dependent lineage plasticity in mature B cells.
Graf R, Seagal J, Otipoby KL, Lam KP, Ayoub S, Zhang B, Sander S, Chu VT, Rajewsky K.
Science. 2019 Feb 15;363(6428):748-753. PMID: 30765568.
Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.
Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B.
PNAS. 2018 Jan 23;115(4): E686-E695. PMID: 29311309.
Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma.
Pasqualucci L and Zhang B.
Semin Cancer Biol. 2016, 39: 26-31. PMID: 27546290.
A Rapid Embryonic Stem Cell-Based Mouse Model for B-cell Lymphomas Driven by Epstein-Barr Virus Protein LMP1.
Ba Z, Meng FL, Gostissa M, Huang PY, Ke Q, Wang Z, Dao MN, Fujiwara Y, Rajewsky K, Zhang B, and Alt FW.
Cancer Immunol Res. 2015, 3(6): 641-9. PMID: 25934172; PMCID: PMC4456688.
An Oncogenic Role for Alternative NF-kB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression.
Zhang B, Calado DP, Wang Z, Frohler S, Kochert K, Qian Y, Koralov S, Schmidt-Supprian M, Sasaki Y, Unitt C, Rodig S, Chen W, Dalla-Favera R, Alt FW, Pasqualucci L, Rajewsky K.
Cell Reports. 2015, 11(5): 715-26. PMID: 25921526; PMCID: PMC4426003.
Studying Epstein-Barr Virus Pathologies and Immune Surveillance by Reconstructing EBV Infection in Mice.
Yasuda T, Wirtz T, Zhang B, Wunderlich T, Schmidt-Supprian M, Sommermann T, Rajewsky K.
Cold Spring Harb Symp Quant Biol. 2013, 78: 259-63. PMID: 24241423.
Synergy between PI3K Signalling and MYC in Burkitt Lymphomagenesis.
Sander S, Calado, DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig S, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K.
Cancer Cell. 2012, 22(2): 167-79. PMID: 22897848; PMCID: PMC3432451.
Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr-Virus Protein LMP1 in a Mouse Model.
Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, Hömig-Hölzel C, Wang Z, Derudder E, Li S, Chakraborty T, Cotter SE, Koyama S, Currie T, Freeman GJ, Kutok JL, Rodig SJ, Dranoff G, Rajewsky K.
Cell. 2012, 148(4): 739-51. PMID: 22341446; PMCID: PMC3313622.
Constitutive canonical NF-kB activation cooperates with disruption of Blimp1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.
Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, Rodig S, Kutok J, Tarakhovsky A, Schmidt-Supprian M, Rajewsky K.
Cancer Cell. 2010, 18(6): 580-9. PMID: 21156282; PMCID: PMC3018685.
Loss of Negative Feedback Control of Nuclear Factor-kappaB2 Activity in Lymphocytes Leads to Fatal Lung Inflammation.
Yang L, Cui H, Wang Z, Zhang B, Ding J, Liu L, Ding HF.
Am J Pathol. 2010, 176(6): 2646-57. PMID: 20363924; PMCID: PMC2877828.
PI3 kinase signals BCR-dependent mature B cell survival.
Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, Kutok JL, Kearney JF, Otipoby KL, Rajewsky K.
Cell. 2009, 139(3): 573-86. PMID: 19879843; PMCID: PMC2787092.
NIK-overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells.
Sasaki Y, Calado DP, Derudder E, Zhang B, Shimizu Y, Mackay F, Nishikawa SI, Rajewsky K, Schmidt-Supprian M.
PNAS. 2008, 105(31): 10883-8. PMID: 18663224; PMCID: PMC2504772.
Constitutive production of NF-kB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.
Wang Z, Zhang B, Yang L, Ding J, Ding HF.
J Biol Chem. 2008, 283(16): 10698-706. PMID: 18281283; PMCID: PMC3762532.
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.
Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K.
Nat Immunol. 2008, 9(4): 405-14. PMID: 18327259; PMCID: PMC2533767.
NF-kB2 mutation targets TRAF1 to induce lymphomagenesis.
Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF.
Blood. 2007, 110(2): 743-51. PMID: 17405906; PMCID: PMC1924489.
NF-kB2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells.
Zhang B, Wang Z, Ding J, Peterson P, Gunning WT, Ding HF.
J Biol Chem. 2006, 281(50): 38617-24. PMID: 17046818; PMCID: PMC1847381.